Hepatocellular Carcinoma Reagents

Home > Featured Products > Oncology Research > Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) accounts for ~90% of primary liver cancers, with chronic HBV/HCV infection and metabolic dysfunction as leading risk factors. The combination of anti-angiogenics (VEGFR TKIs) and checkpoint inhibitors has reshaped first-line HCC treatment. abinScience provides reagents for AFP, GPC3, HBV/HCV antigens, VEGF/VEGFR, EpCAM, and PD-1/PD-L1. RUO

Key Biomarkers & Targets

AFP

Alpha-Fetoprotein

Classic serum biomarker for HCC screening and monitoring. Also an emerging bispecific/ADC target. 30 antibodies and proteins.

Antibodies • Proteins

GPC3

Glypican-3

HCC-specific cell-surface marker; target for CAR-T, bispecifics, and ADCs. 29 antibodies and biosimilar proteins.

Antibodies • Biosimilars

HBV / HCV

Hepatitis Viral Antigens

HBsAg, HBcAg, HBe, and HCV Core/NS3/NS5 antigens and antibodies for viral hepatitis and HCC etiology research. 120+ products.

Antibodies • Proteins

VEGF / VEGFR

Angiogenesis Pathway

Sorafenib, lenvatinib, and bevacizumab all target the VEGF axis in HCC. 190+ combined antibodies, proteins, and biosimilars.

Antibodies • Proteins • Biosimilars

EpCAM / TACSTD1

Epithelial Cell Adhesion

EpCAM-positive HCC cells represent hepatic cancer stem cells and are associated with poor prognosis. 44 antibodies and proteins.

Antibodies • Biosimilars

PD-1 / PD-L1 / CTLA-4

Immune Checkpoints

Atezolizumab + bevacizumab is the first-line standard in advanced HCC. 400+ combined checkpoint reagents.

Antibodies • Proteins • Biosimilars

Why Researchers Choose abinScience for HCC

HCC-Specific Target CoverageAFP, GPC3, and Wnt/β-catenin pathway reagents — targets with high HCC specificity for immunotherapy and diagnostic R&D.

Viral Hepatitis Antigen LibraryHBV (HBsAg, HBcAg, HBeAg) and HCV (Core, NS3, NS5) recombinant antigens and antibodies for etiology research and serodiagnostic assay development.

Anti-Angiogenic Drug ResearchVEGF-A, VEGFR1/2, FGFR, and MET proteins and antibodies for studying multi-kinase inhibitor response and resistance in HCC.

Protein–Antibody–Kit WorkflowSame target as recombinant protein, detection antibody, and ELISA kit from one manufacturer for streamlined assay development.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

AFP-based HCC surveillance: Develop and validate serum AFP immunoassays using our anti-AFP matched antibody pairs and recombinant AFP protein standards for liver cancer screening programs.
GPC3-targeted immunotherapy: Quantify GPC3 expression (IHC/FC) for patient stratification and use recombinant GPC3 proteins for CAR-T binding validation and bispecific antibody characterization.
Viral hepatitis-HCC nexus: Characterize HBV/HCV antigen expression in liver tissue and correlate with hepatocarcinogenesis biomarkers (AFP, GPC3, p53) across disease progression stages.
Anti-angiogenic combination studies: Profile VEGF/VEGFR, FGFR, and MET expression to understand resistance to sorafenib/lenvatinib and rationale for checkpoint inhibitor combinations in HCC.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you offer AFP antibody pairs for ELISA?

Yes. We carry anti-AFP monoclonal antibodies and recombinant AFP proteins suitable for sandwich ELISA development for HCC serum screening applications.

Which GPC3 antibodies are suitable for CAR-T target validation?

Our anti-GPC3 monoclonal antibodies detect cell-surface GPC3 by IHC and flow cytometry. Recombinant GPC3-ECD proteins are available for CAR construct binding characterization.

Do you carry recombinant HBV antigens?

Yes — we offer recombinant HBsAg, HBcAg, and HBeAg proteins produced in mammalian expression systems, suitable for serodiagnostic assay development and vaccine research.

What IHC markers distinguish HCC from cholangiocarcinoma?

HCC is typically Hep Par-1+, GPC3+, AFP+, CK19−. Cholangiocarcinoma shows CK19+, CK7+, EpCAM+, GPC3−. We offer antibodies for all these markers.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.